Coronavirus

HGGC sees opportunities to back dislocated assets in the public markets and also eyes win-win partnership transactions.

While Varma is supportive of a shutdown, he said the medical damage to patients with other diseases is going to become insurmountable.

PE firms move slowly into offense mode amid the coronavirus crisis and Thoma Bravo shelves its sale of Imprivata.

Despite the current coronavirus crisis, deals are being prepped.

Across the private equity industry, the impacts of the pandemic-spurred economic downturn are being felt in dealmaking, which has slowed or paused fundraising processes while LPs work to understand the status of their portfolios.

COVID-19 crisis could bode well for new M&A tech opportunities and Gryphon launches sixth fund.

Available capital and promise of consumer staples keep sponsors around but most companies will not seal deals in the near term.

While many traditional PE shops are busy assessing the potential impacts of covid-19 on their portfolios, a few are turning to their companies to develop vaccines and tests to curb the spread of coronavirus.

Amid the COVID-9 crisis, some firms are invoking the MAC clause to pull out of deals.

The turnaround expert shares his take on covid-19's impact on PE, asserting that he's seeing MAC clauses implemented for the first time in his 20-year career.